Constellation Pharmaceuticals Competitors

Biohaven Pharmaceutical (NYSE:BHVN) and Constellation Pharmaceuticals (NASDAQ:CNST) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Biohaven Pharmaceutical has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

Institutional and Insider Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Biohaven Pharmaceutical and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Biohaven Pharmaceutical and Constellation Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Biohaven Pharmaceutical and Constellation Pharmaceuticals, as provided by MarketBeat.com.

Biohaven Pharmaceutical currently has a consensus price target of $96.4545, suggesting a potential upside of 39.00%. Constellation Pharmaceuticals has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Given Constellation Pharmaceuticals' higher probable upside, analysts plainly believe Constellation Pharmaceuticals is more favorable than Biohaven Pharmaceutical.

Summary

Constellation Pharmaceuticals beats Biohaven Pharmaceutical on 6 of the 11 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Constellation Pharmaceuticals (NASDAQ:CNST) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Hutchison China MediTech has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

Institutional and Insider Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. 10.6% of Constellation Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Hutchison China MediTech and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Hutchison China MediTech and Constellation Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Constellation Pharmaceuticals has lower revenue, but higher earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Constellation Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Hutchison China MediTech and Constellation Pharmaceuticals, as provided by MarketBeat.com.

Hutchison China MediTech currently has a consensus price target of $40.00, suggesting a potential upside of 36.80%. Constellation Pharmaceuticals has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Given Constellation Pharmaceuticals' higher probable upside, analysts plainly believe Constellation Pharmaceuticals is more favorable than Hutchison China MediTech.

Emergent BioSolutions (NYSE:EBS) and Constellation Pharmaceuticals (NASDAQ:CNST) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Emergent BioSolutions has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

Institutional and Insider Ownership

80.2% of Emergent BioSolutions shares are owned by institutional investors. 14.1% of Emergent BioSolutions shares are owned by insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Emergent BioSolutions and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Emergent BioSolutions and Constellation Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Emergent BioSolutions has higher revenue and earnings than Constellation Pharmaceuticals. Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Emergent BioSolutions and Constellation Pharmaceuticals, as provided by MarketBeat.com.

Emergent BioSolutions currently has a consensus price target of $109.8333, suggesting a potential upside of 42.00%. Constellation Pharmaceuticals has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Given Constellation Pharmaceuticals' higher probable upside, analysts plainly believe Constellation Pharmaceuticals is more favorable than Emergent BioSolutions.

Summary

Emergent BioSolutions beats Constellation Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

Arena Pharmaceuticals (NASDAQ:ARNA) and Constellation Pharmaceuticals (NASDAQ:CNST) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current ratings for Arena Pharmaceuticals and Constellation Pharmaceuticals, as provided by MarketBeat.com.

Arena Pharmaceuticals currently has a consensus price target of $91.80, suggesting a potential upside of 38.48%. Constellation Pharmaceuticals has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Given Constellation Pharmaceuticals' higher probable upside, analysts plainly believe Constellation Pharmaceuticals is more favorable than Arena Pharmaceuticals.

Volatility & Risk

Arena Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

Profitability

This table compares Arena Pharmaceuticals and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Arena Pharmaceuticals and Constellation Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Constellation Pharmaceuticals. Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Constellation Pharmaceuticals (NASDAQ:CNST) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Constellation Pharmaceuticals and Turning Point Therapeutics, as provided by MarketBeat.

Constellation Pharmaceuticals currently has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Turning Point Therapeutics has a consensus price target of $153.7143, suggesting a potential upside of 94.70%. Given Constellation Pharmaceuticals' higher probable upside, equities research analysts plainly believe Constellation Pharmaceuticals is more favorable than Turning Point Therapeutics.

Risk and Volatility

Constellation Pharmaceuticals has a beta of 2.8, indicating that its share price is 180% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Profitability

This table compares Constellation Pharmaceuticals and Turning Point Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. 10.6% of Constellation Pharmaceuticals shares are held by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Constellation Pharmaceuticals and Turning Point Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Constellation Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Turning Point Therapeutics beats Constellation Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

Constellation Pharmaceuticals (NASDAQ:CNST) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Constellation Pharmaceuticals and Legend Biotech, as provided by MarketBeat.

Constellation Pharmaceuticals currently has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Legend Biotech has a consensus price target of $50.6667, suggesting a potential upside of 78.09%. Given Constellation Pharmaceuticals' higher probable upside, equities research analysts plainly believe Constellation Pharmaceuticals is more favorable than Legend Biotech.

Profitability

This table compares Constellation Pharmaceuticals and Legend Biotech's net margins, return on equity and return on assets.

Institutional & Insider Ownership

18.9% of Legend Biotech shares are held by institutional investors. 10.6% of Constellation Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Constellation Pharmaceuticals and Legend Biotech's gross revenue, earnings per share (EPS) and valuation.

Constellation Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech.

Summary

Constellation Pharmaceuticals beats Legend Biotech on 7 of the 10 factors compared between the two stocks.